… -thrombotic syndrome. Here, we review the link between inflammation and deep vein thrombosis
… the treatment of deep vein thrombosis and the prevention of post-thrombotic syndrome. …

… most often in the legs or arms, a process known as deep vein thrombosis 10 . These clots …
as pulmonary embolism (PE). Deep vein thrombosis and PE are collectively known as venous …

… Results of a recent trial comparing antisense-induced factor XI reduction to standard-dose
low molecular–weight heparin as prophylaxis for venous thrombosis during knee replacement …

… also identify potential (adjunctive) therapeutic targets for thromboprophylaxis that do not
modify bleeding risk. In this issue of the Journal of Thrombosis and Haemostasis, Tilburg et al …

… FXII and prekallikrein have been demonstrated in vivo using FeCl3- induced and stenosis-induced
models of venous thrombosis (114). Different approaches, such as the use of …

… vein thrombosis is associated with an increased risk of VTE for more than 5 years after the
thrombotic … currently in clinical use are enzyme-specific and target either factor Xa or thrombin (…

… thrombosis is treated with drugs that target platelets, and venous thrombosis is treated with
drugs that target … makes it difficult to identify therapeutic targets. An exception seems to be the …

… therapies targeted to the platelet. Additionally, we highlight the promising receptor and enzymatic
targets … The pathophysiological mechanisms of arterial and venous thrombus formation …

… to arterial thrombosis and contributes to venous thromboembolism. Mouse models have
shown a critical role of FXII in deep vein thrombosis. Stasis-driven deep vein thrombosis in the …

… Deep venous thrombosis is a frequent, multifactorial disease … Most of the time deep venous
thrombosis is triggered by the … thrombosis and therefore can be used as a therapeutic target…